- Home
- CPZ vs ABEO Comparison
CPZ vs ABEO Comparison
Compare CPZ & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPZ
- ABEO
- Stock Information
- Founded
- CPZ 2019
- ABEO 1974
- Country
- CPZ United States
- ABEO United States
- Employees
- CPZ N/A
- ABEO N/A
- Industry
- CPZ Trusts Except Educational Religious and Charitable
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- CPZ Finance
- ABEO Health Care
- Exchange
- CPZ Nasdaq
- ABEO Nasdaq
- Market Cap
- CPZ 328.3M
- ABEO 332.0M
- IPO Year
- CPZ N/A
- ABEO 1980
- Fundamental
- Price
- CPZ $16.72
- ABEO $6.83
- Analyst Decision
- CPZ
- ABEO Strong Buy
- Analyst Count
- CPZ 0
- ABEO 6
- Target Price
- CPZ N/A
- ABEO $18.17
- AVG Volume (30 Days)
- CPZ 63.0K
- ABEO 702.3K
- Earning Date
- CPZ 01-01-0001
- ABEO 08-14-2025
- Dividend Yield
- CPZ 11.07%
- ABEO N/A
- EPS Growth
- CPZ N/A
- ABEO N/A
- EPS
- CPZ N/A
- ABEO 0.99
- Revenue
- CPZ N/A
- ABEO $400,000.00
- Revenue This Year
- CPZ N/A
- ABEO N/A
- Revenue Next Year
- CPZ N/A
- ABEO $339.63
- P/E Ratio
- CPZ N/A
- ABEO $6.91
- Revenue Growth
- CPZ N/A
- ABEO N/A
- 52 Week Low
- CPZ $13.17
- ABEO $3.93
- 52 Week High
- CPZ $16.11
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- CPZ 60.18
- ABEO 52.71
- Support Level
- CPZ $16.50
- ABEO $6.70
- Resistance Level
- CPZ $16.70
- ABEO $7.15
- Average True Range (ATR)
- CPZ 0.18
- ABEO 0.31
- MACD
- CPZ 0.00
- ABEO -0.02
- Stochastic Oscillator
- CPZ 81.40
- ABEO 46.62
About CPZ Calamos Long/Short Equity & Dynamic Income Trust
Calamos L/S Equity & Dynamic Inc Trust is a trust company which seeks to provide current income and risk-managed capital appreciation. The company invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary and others.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.